BALTIMORE, June 9, 2011 /PRNewswire/ -- Paragon Bioservices, Inc., a Baltimore-based contract research and GMP manufacturing organization, announced today that representatives from the company will be participating in the 2011 BIO International Convention’s One-on-One Partnering Meetings being held on June 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.
Founded in 1990, Paragon Bioservices is a CMC Center of Excellence delivering research, development and cGMP manufacturing services to pharmaceutical companies, biotechnology companies and federal agencies. With a focus on vaccines (VLPs), monoclonal antibodies, therapeutic proteins and stem cells, Paragon’s role is to bridge the translational divide and to enable vaccinesas well as proteins and cell-based therapeuticsto move from the research bench into Phase I/II clinical trials.
Representatives available to discuss Paragon’s capabilities include: Dr. Marco Chacon, President & CEO; Jessica Boehmer, Director of Sales & Business Development; Dr. Philip Wills, Corporate Scientific Liaison; and Dr. Aaron Heifetz, Stem Cell & Regenerative Medicine. Companies or individuals attending BIO 2011 can schedule meetings with Paragon by visiting: http://oneononepartnering.bio.org/BusinessForum2011/Login.aspx.
Partnering Schedule: | ||
Monday, June 27 | Business Forum - 12:00 p.m. 5:00 p.m. | |
Tuesday, June 28 | Business Forum - 8:00 p.m. 5:00 p.m. | |
Wednesday, June 29 | Business Forum - 8:00 a.m. 5:00 p.m. | |
Thursday, June 30 | Business Forum - 8:00 a.m. 5:00 p.m. | |
For companies or individuals not participating in partnering meetings, Paragon will be exhibiting in booth number 1657 located in Hall A BIO Process Zone.
About Paragon Bioservices, Inc.
Located in Baltimore, Maryland, Paragon Bioservices is a privately held contract research and manufacturing organization (CMO) with a focus on the development and manufacturing of biopharmaceuticalseither for research purposes or clinical trials. Working as an outsourcing partner and with a long standing tradition of quality and service, Paragon expands the capabilities of pharmaceutical companies, biotechnology companies and government agencies involved in the development of monoclonal antibodies, therapeutic proteins, vaccines/VLPs and stem cells.
For more information visit: www.paragonbioservices.com.
Media Contacts:
Tiberend Strategic Advisors, Inc. (212) 827-0020
Tamara Brighttbright@tiberend.com or Claire Sojdacsojda@tiberend.com
SOURCE Paragon Bioservices, Inc.
